The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients
Open accessThe DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
Coronavirus disease 2019 (COVID-19) pandemic has affected health care systems worldwide. Severe presentations of COVID-19 such as severe pneumonia and acute respiratory distress syndrome (ARDS) have been associated with the post-viral activation and release of cytokine/chemokines which leads to a “cytokine storm” causing inflammatory response and destruction, mainly affecting the lungs. COVID-19 activation of transcription factor, NF-kappa B (NF-κB) in various cells such as macrophages of lung, liver, kidney, central nervous system, gastrointestinal system and cardiovascular system leads to production of IL-1, IL-2, IL-6, IL-12, TNF-α, LT-α, LT-β, GM-CSF, and various chemokines. The sensitised NF-κB in elderly and in patients with metabolic syndrome makes this set of population susceptible to COVID-19 and their worse complications, including higher mortality. Immunomodulation at the level of NF-κB activation and inhibitors of NF-κB (IκB) degradation along with TNF-α inhibition will potentially result in a reduction in the cytokine storm and alleviate the severity of COVID-19. Inhibition of NF-κB pathway has a potential therapeutic role in alleviating the severe form of COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · cited 1×
“The structure of the receptor-binding gene region is very similar to that of the SARS coronavirus; and the virus uses the same receptor, the angiotensin-1-converting enzyme 2 (ACE2), for cell entry (Zhou et al. 2020).”
MethodA new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475
NF-κB signaling in inflammation
Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.23 · Cited by 8,791
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Factors associated with COVID-19-related death using OpenSAFELY
Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2521-4 · Cited by 6,674
The Nuclear Factor NF- B Pathway in Inflammation
Lawrence, T. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001651 · Cited by 4,898
Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., & Zhou, Y. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.017 · Cited by 4,206
NF-κB regulation in the immune system
Li, Q., & Verma, I. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri910 · Cited by 4,007
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510 · cited 10×
“NF‑κB pathway‑ the link between metabolic syndrome and COVID‑19?”
ResultInfluentialThe NF- B Family of Transcription Factors and Its Regulation
Oeckinghaus, A., & Ghosh, S. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000034 · Cited by 2,842
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., & Karin, M. (1995) · Science · doi:10.1126/science.270.5234.286 · Cited by 2,390
30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology
Zhang, Q., Lenardo, M. J., & Baltimore, D. (2017) · Cell · doi:10.1016/j.cell.2016.12.012 · Cited by 1,982
NF-κB, Inflammation, and Metabolic Disease
Baker, R. G., Hayden, M. S., & Ghosh, S. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2010.12.008 · Cited by 1,952 · cited 1×
“Apart from association with the “cytokine storm”, the NF-κB pathway is well known to be associated with the pathogenesis of metabolic syndrome (Baker et al. 2011; Urso 2020).”
BackgroundThe non-canonical NF-κB pathway in immunity and inflammation
Sun, S.-C. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.52 · Cited by 1,891
Acute kidney injury in patients hospitalized with COVID-19
Hirsch, J. S., Ng, J. H., Ross, D. W., Sharma, P., Shah, H. H., Barnett, R. L., Hazzan, A. D., Fishbane, S., Jhaveri, K. D., Abate, M., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.05.006 · Cited by 1,523
Remdesivir for the Treatment of Covid-19 — Preliminary Report
(2020) · New England Journal of Medicine · doi:10.1056/nejmc2022236 · Cited by 1,396
Why does COVID-19 disproportionately affect older people?
Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020) · Aging · doi:10.18632/aging.103344 · Cited by 1,128
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease
Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C., & Melguizo-Rodríguez, L. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.001 · Cited by 1,121
Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., & Wen, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01708 · Cited by 1,094 · cited 1×
“Since the emergence of COVID 19, in most severe cases an elevated level of proinflammatory factors such as, IL-2, IL-1, IL-6, IFN-γ, MIP1α, MCP1 and TNF-α have been reported (Tang et al. 2020; Costela-Ruiz et al. 2020).”
BackgroundKnoops, K., Kikkert, M., Worm, S. H. E. V. D., Zevenhoven-Dobbe, J. C., van der Meer, Y., Koster, A. J., Mommaas, A. M., & Snijder, E. J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060226 · Cited by 1,015
COVID-19 in people with diabetes: understanding the reasons for worse outcomes
Apicella, M., Campopiano, M. C., Mantuano, M., Mazoni, L., Coppelli, A., & Del Prato, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30238-2 · Cited by 903
PKR; a sentinel kinase for cellular stress
Williams, B. R. (1999) · Oncogene · doi:10.1038/sj.onc.1203127 · Cited by 820 · cited 2×
“In addition, upon binding to dsRNA, the PKR (gets activated as a kinase enzyme), which also activates the inhibitor of IκB kinase (IKK), leading to the degradation of the inhibitors IκBα and IκBβ and the concomitant release of NF-κB (Williams 1999; D’Acquisto et al.”
BackgroundCytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment
Soy, M., Keser, G., Atagündüz, P., Tabak, F., Atagündüz, I., & Kayhan, S. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05190-5 · Cited by 811
COVID-19: a new virus, but a familiar receptor and cytokine release syndrome
Hirano, T., & Murakami, M. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.003 · Cited by 772
NF-κB Signaling in Macrophages: Dynamics, Crosstalk, and Signal Integration
Dorrington, M. G., & Fraser, I. D. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00705 · Cited by 717
p38-dependent marking of inflammatory genes for increased NF-κB recruitment
Saccani, S., Pantano, S., & Natoli, G. (2002) · Nature Immunology · doi:10.1038/ni748 · Cited by 693
Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review
Montalvan, V., Lee, J., Bueso, T., De Toledo, J., & Rivas, K. (2020) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2020.105921 · Cited by 647
Zhu, Z., Lian, X., Su, X., Wu, W., Marraro, G. A., & Zeng, Y. (2020) · Respiratory Research · doi:10.1186/s12931-020-01479-w · Cited by 614
Catanzaro, M., Fagiani, F., Racchi, M., Corsini, E., Govoni, S., & Lanni, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0191-1 · Cited by 605
Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection
Delgado-Roche, L., & Mesta, F. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.04.019 · Cited by 604
The nuclear factor- B-interleukin-6 signalling pathway mediating vascular inflammation
Brasier, A. R. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq076 · Cited by 586
Salminen, A., Huuskonen, J., Ojala, J., Kauppinen, A., Kaarniranta, K., & Suuronen, T. (2008) · Ageing Research Reviews · doi:10.1016/j.arr.2007.09.002 · Cited by 581
Sanz, A. B., Sanchez-Niño, M. D., Ramos, A. M., Moreno, J. A., Santamaria, B., Ruiz-Ortega, M., Egido, J., & Ortiz, A. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010020218 · Cited by 567
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
Feldmann, M., Maini, R. N., Woody, J. N., Holgate, S. T., Winter, G., Rowland, M., Richards, D., & Hussell, T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30858-8 · Cited by 536
Inhibition of NF- B DNA Binding by Nitric Oxide
Matthews, J. R., Botting, C. H., Panico, M., Morris, H. R., & Hay, R. T. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.12.2236 · Cited by 495
Sulindac Inhibits Activation of the NF-κB Pathway
Yamamoto, Y., Yin, M.-J., Lin, K.-M., & Gaynor, R. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.38.27307 · Cited by 494
Devaux, C. A., Rolain, J.-M., & Raoult, D. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.04.015 · Cited by 476
DeDiego, M. L., Nieto-Torres, J. L., Regla-Nava, J. A., Jimenez-Guardeño, J. M., Fernandez-Delgado, R., Fett, C., Castaño-Rodriguez, C., Perlman, S., & Enjuanes, L. (2014) · Journal of Virology · doi:10.1128/jvi.02576-13 · Cited by 394
Coronavirus breakthrough: dexamethasone is first drug shown to save lives
Ledford, H. (2020) · Nature · doi:10.1038/d41586-020-01824-5 · Cited by 356
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
Schett, G., Sticherling, M., & Neurath, M. F. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0312-7 · Cited by 349
Inflammation and the Metabolic Syndrome: The Tissue-Specific Functions of NF-κB
Catrysse, L., & van Loo, G. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.01.006 · Cited by 329 · cited 1×
“Thus the overnutrition, obesity-induced excess metabolites, hyperlipidemia and hyperglycemia, are risk factors that initiate and propagate hyper-activation of the NF-κB pathway, leading to severe COVID-19 and worse outcomes (Catrysse and Loo 2017; Apicella et al.”
Backgroundp38 MAPK inhibition: A promising therapeutic approach for COVID-19
Grimes, J. M., & Grimes, K. V. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.05.007 · Cited by 259
Hamid, T., Guo, S. Z., Kingery, J. R., Xiang, X., Dawn, B., & Prabhu, S. D. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq274 · Cited by 252
Singh, A. K., Majumdar, S., Singh, R., & Misra, A. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.06.054 · Cited by 252
Inhibition of Nuclear Factor Kappa B (NF-B):: An Emerging Theme in Anti-Inflammatory Therapies
D'Acquisto, F. (2002) · Molecular Interventions · doi:10.1124/mi.2.1.22 · Cited by 237
Dosch, S. F., Mahajan, S. D., & Collins, A. R. (2009) · Virus Research · doi:10.1016/j.virusres.2009.01.005 · Cited by 228
Ye, Z., Wang, Y., Colunga-Lozano, L. E., Prasad, M., Tangamornsuksan, W., Rochwerg, B., Yao, L., Motaghi, S., Couban, R. J., Ghadimi, M., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.200645 · Cited by 225
Renal complications in COVID-19: a systematic review and meta-analysis
Kunutsor, S. K., & Laukkanen, J. A. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1790643 · Cited by 207
Cytokine storm syndrome in coronavirus disease 2019: A narrative review
Gao, Y. ‐., Xu, G., Wang, B., & Liu, B. ‐. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13144 · Cited by 202
Shalhoub, S., Farahat, F., Al-Jiffri, A., Simhairi, R., Shamma, O., Siddiqi, N., & Mushtaq, A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv085 · Cited by 189
N‐Acetylcysteine suppresses TNF‐induced NF‐κB activation through inhibition of IκB kinases
Oka, S.-I., Kamata, H., Kamata, K., Yagisawa, H., & Hirata, H. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01464-2 · Cited by 186
COVID 19: a clue from innate immunity
Birra, D., Benucci, M., Landolfi, L., Merchionda, A., Loi, G., Amato, P., Licata, G., Quartuccio, L., Triggiani, M., & Moscato, P. (2020) · Immunologic Research · doi:10.1007/s12026-020-09137-5 · Cited by 166
Understanding the renin–angiotensin–aldosterone–SARS-CoV axis: a comprehensive review
Ingraham, N. E., Barakat, A., Reilkoff, R. A., Bezdicek, T. L., Schacker, T. W., Chipman, J. G., Tignanelli, C. J., & Puskarich, M. A. (2020) · European Respiratory Journal · doi:10.1183/13993003.00912-2020 · Cited by 165
BMP4 Inhibits Breast Cancer Metastasis by Blocking Myeloid-Derived Suppressor Cell Activity
Cao, Y., Slaney, C. Y., Bidwell, B. N., Parker, B. S., Johnstone, C. N., Rautela, J., Eckhardt, B. L., & Anderson, R. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3171 · Cited by 149
Sex Hormones and Novel Corona Virus Infectious Disease (COVID-19)
Al-Lami, R. A., Urban, R. J., Volpi, E., Algburi, A., & Baillargeon, J. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.05.013 · Cited by 146
Thrombotic microangiopathy in a patient with COVID-19
Jhaveri, K. D., Meir, L. R., Chang, B. S. F., Parikh, R., Wanchoo, R., Barilla-LaBarca, M.-L., Bijol, V., & Hajizadeh, N. (2020) · Kidney International · doi:10.1016/j.kint.2020.05.025 · Cited by 144
Day, C. W., Baric, R., Cai, S. X., Frieman, M., Kumaki, Y., Morrey, J. D., Smee, D. F., & Barnard, D. L. (2009) · Virology · doi:10.1016/j.virol.2009.09.023 · Cited by 140
Wu, Z., Hu, R., Zhang, C., Ren, W., Yu, A., & Zhou, X. (2020) · Critical Care · doi:10.1186/s13054-020-03015-0 · Cited by 138
Azithromycin for COVID-19: More Than Just an Antimicrobial?
Bleyzac, N., Goutelle, S., Bourguignon, L., & Tod, M. M. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00933-3 · Cited by 133
Age and sex differences in soluble ACE2 may give insights for COVID-19
Swärd, P., Edsfeldt, A., Reepalu, A., Jehpsson, L., Rosengren, B. E., & Karlsson, M. K. (2020) · Critical Care · doi:10.1186/s13054-020-02942-2 · Cited by 128
An Insight into the Sex Differences in COVID-19 Patients: What are the Possible Causes?
Maleki Dana, P., Sadoughi, F., Hallajzadeh, J., Asemi, Z., Mansournia, M. A., Yousefi, B., & Momen-Heravi, M. (2020) · Prehospital and Disaster Medicine · doi:10.1017/s1049023x20000837 · Cited by 114
Zhang, Y.-Y., Li, B.-R., & Ning, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02033 · Cited by 112
High-glucose-induced nuclear factor κB activation in vascular smooth muscle cells
Hattori, Y. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00425-3 · Cited by 111
Covid-19: what treatments are being investigated?
Mahase, E. (2020) · BMJ · doi:10.1136/bmj.m1252 · Cited by 108
Activation of NF-κB by the Full-length Nucleocapsid Protein of the SARS Coronavirus
Liao, Q., Ye, L.-B., Timani, K. A., Zen, Y., She, Y., Li, Y., & Wu, Z.-H. (2005) · Acta Biochimica et Biophysica Sinica · doi:10.1111/j.1745-7270.2005.00082.x · Cited by 98
Battagello, D. S., Dragunas, G., Klein, M., Ayub, A. L. P., Velloso, F. J., & Correa, R. G. (2020) · Clinical Science · doi:10.1042/cs20200904 · Cited by 89
c-Jun NH2-terminal Kinase-mediated Redox-dependent Degradation of IκB
Das, K. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006206200 · Cited by 82
WU, X.-Y., Luo, A., ZHOU, Y.-R., & Ren, J.-H. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2292 · Cited by 76
The non-canonical NF-κB pathway and its contribution to β-cell failure in diabetes
Meyerovich, K., Ortis, F., & Cardozo, A. K. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0183 · Cited by 75
Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin
Mozafari, N., Azadi, S., Mehdi-Alamdarlou, S., Ashrafi, H., & Azadi, A. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110111 · Cited by 71
COVID-19 as a STING disorder with delayed over-secretion of interferon-beta
Berthelot, J., & Lioté, F. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102801 · Cited by 64
Nuclear factor κB–inducing kinase activation as a mechanism of pancreatic β cell failure in obesity
Malle, E. K., Zammit, N. W., Walters, S. N., Koay, Y. C., Wu, J., Tan, B. M., Villanueva, J. E., Brink, R., Loudovaris, T., Cantley, J., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150218 · Cited by 63
Bauer, S. R., Kapoor, A., Rath, M., & Thomas, S. A. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.ccc046 · Cited by 61
Meusel, T. R., Kehoe, K. E., & Imani, F. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6429 · Cited by 52
Dexamethasone: A boon for critically ill COVID-19 patients?
Patel, S. K., Saikumar, G., Rana, J., Dhama, J., Yatoo, M. I., Tiwari, R., Rodriguez-Morales, A. J., & Dhama, K. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101844 · Cited by 45
Activation of NF-kB Pathway by Virus Infection Requires Rb Expression
García, M. Á., Gallego, P. P. F., Campagna, M., González, J., Martinez, G. M., Marcos-Villar, L., Vidal, A., Estéban, M., & Rivas, C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006422 · Cited by 41
Liang, N., Zhong, Y., Zhou, J., Liu, B., Lu, R., Guan, Y., Wang, Q., Liang, C., He, Y., Zhou, Y., et al. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.5708 · Cited by 41
Anti-inflammatory Activity of Azithromycin as Measured by Its NF-кB Inhibitory Activity
Cheung, P. S., Si, E. C., & Hosseini, K. (2010) · Ocular Immunology and Inflammation · doi:10.3109/09273940903359725 · Cited by 39
Krause, M. D. S., Gerchman, F., & Friedman, R. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00572-w · Cited by 37
Sanghai, N., & Tranmer, G. K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.013 · Cited by 37
Assimakopoulos, S. F., & Marangos, M. N. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109778 · Cited by 33
Pozo, O. J., Marcos, J., Khymenets, O., Pranata, A., Fitzgerald, C. C., McLeod, M. D., & Shackleton, C. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0286 · Cited by 30
Old and new antirheumatic drugs for the treatment of COVID-19
Benucci, M., Damiani, A., Infantino, M. G., Manfredi, M., & Quartuccio, L. (2020) · Joint Bone Spine · doi:10.1016/j.jbspin.2020.03.013 · Cited by 30
Cited by
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 603
SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB
Neufeldt, C. J., Cerikan, B., Cortese, M., Frankish, J., Lee, J.-Y., Plociennikowska, A., Heigwer, F., Prasad, V., Joecks, S., Burkart, S. S., et al. (2022) · Communications Biology · doi:10.1038/s42003-021-02983-5 · Cited by 272
Metadata
- Authors
- Hariharan, A., Hakeem, A. R., Radhakrishnan, S., Reddy, M. S., & Rela, M.
- Venue
- Inflammopharmacology
- Published
- 2020-11-07
- Volume
- 29
- Issue
- 1
- Pages
- 91-100
- ISSN
- 0925-4692 (ISSN-L)
- 1568-5608
- OpenAlex
- W3096634408
- Cited by
- 295
- References
- 86
- FWCI
- 15.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.